

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of
LI ET AL.

Examiner: NOT YET ASSIGNED

Art Unit: NOT YET ASSIGNED

Application No.: NOT YET ASSIGNED

Filed: **HEREWITH**

Title: **METHOD FOR ASSAYING COMPOUNDS
OR AGENTS FOR ABILITY TO
DECREASE THE ACTIVITY OF
MICROSOMAL PROSTAGLANDIN E
SYNTHASE OR HEMATOPOIETIC
PROSTAGLANDIN D SYNTHASE**

I hereby certify that this correspondence is being
deposited with the United States Postal Service as
Express Mail in an envelope addressed to
Commissioner for Patents, Washington, D.C. 20231, on

8/15/03
Date of Deposit
Signature

EV330283003US


Express Mail No.

STATEMENT REGARDING CONTENT OF PAPER AND COMPUTER READABLE COPIES PURSUANT TO 37 C.F.R. 1.821 (f)

Mail Stop Patent Applications
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

The undersigned states that the content of the nucleotide and/or amino acid sequences set forth in the "Sequence Listing" part of the enclosed patent application required by 37 C.F.R. 1.821 (c) and the computer readable copies required by 37 C.F.R. 1.821 (e) submitted herewith are the same.

Respectfully submitted,


William C. Coppola, Reg. No. 41,686

Aventis Pharmaceuticals Inc.
Patent Department
Route #202-206 / P.O. Box 6800
Bridgewater, New Jersey 08807-0800
Telephone (908) 231-4854
Telefax (908) 231-2626

Aventis Docket No. USAV2002/0098 US NP